Winton Group’s Actinium Pharmaceuticals ATNM Stock Holding History

Winton Group’s Portfolio ATNM Stock Details ATNM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-20,382	Closed	-$151K	–	767
2023 Q2	$151K	Buy	+20,382	New	+$173K	0.01%	691

Other funds holding ATNM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

BGIM

Brandywine Global Investment Management Philadelphia, Pennsylvania $14.9B AUM 20.41% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return

Winton Group's ATNM Position: Q3 2023 in Review

Winton Group sold out of Actinium Pharmaceuticals (ATNM) in Q3 2023, closing a stake of 20,382 shares — an estimated $151K sold.

Winton Group first reported a position in ATNM in Q2 2023 and held it in 1 quarter. The position peaked at $151K in Q2 2023. 58 funds tracked by Wall St. Rank hold ATNM as of Q3 2023.

Winton Group reported no remaining Actinium Pharmaceuticals position as of Q3 2023 after selling out during the quarter.
Winton Group sold 20,382 Actinium Pharmaceuticals shares in Q3 2023, an estimated $151K.
Winton Group first reported a position in Actinium Pharmaceuticals in Q2 2023 and held it in 1 quarter.
Winton Group's Actinium Pharmaceuticals position peaked at $151K in Q2 2023.
58 funds tracked by Wall St. Rank held Actinium Pharmaceuticals as of Q3 2023.

Based on Winton Group's 13F filing for Q3 2023, filed 13 Nov 2023.